ablet splitting is a practice that is becoming more popular within managed care pharmacies as the costs of medications increase. For many medications, tablet strengths are identical or similar in cost, and splitting tablets can lower the cost per dose by 40% to 50%. Tablet-splitting programs targeted at high-cost, similarly priced, and widely prescribed medications have expanded in the managed care setting to include a multitude of medications such as ACE-inhibitors (fosinopril, lisinopril, moexipril, and trandolapril), angiotensin II receptor blockers (irbesartan and losartan), Cox-2 inhibitors (rofecoxib and valdecoxib), hydroxymethylglutaryl-CoA reductase inhibitors (HMGs) (atorvastatin, lovastatin, pravastatin, and simvastatin), antidepressants (citalopram, mirtazapine, paroxetine, sertraline, and venlafaxine), carvedilol, cetirizine, metoprolol, nefazodone, sildenafil, and zafirlukast.
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From previous studies, it has been shown that tablet splitting is well accepted by patients and has no effect on compliance. [1] [2] [3] Acceptance and compliance were addressed in these studies with the use of questionnaires and pill counts. One of the studies also calculated a 50% reduction in median annual acquisition cost. 2 Two studies measured the effects of tablet splitting on clinical outcomes. The first study was a randomized, crossover trial consisting of 29 patients taking lisinopril. In this study, both groups took whole tablets for 2 weeks and split tablets for 2 weeks. 3 There was no significant difference in blood pressure between patients taking whole versus split tablets. However, this study had a small sample size, and the duration for each treatment arm was short. The second study was a retrospective chart review analysis, which evaluated the effects of tablet splitting on the lipid panels of 125 patients taking simvastatin and atorvastatin. 4 Patients were required to remain on the same dose at least 6 weeks before and after tablet-splitting initiation, and lipid panels were drawn at least 6 weeks after initiation of wholetablet and half-tablet dosing. There was a statistically, but not clinically, significant reduction in LDL and total cholesterol levels, and no significant change in HDL and triglyceride levels. This study did not review ultimate clinical outcomes and, similar to the first study, had a small sample size.
In an effort to maximize valuable patient resources, a tabletsplitting program was implemented at the Veterans Affairs Palo Alto Health Care System in April 2000. The medications included in our program were simvastatin, lovastatin, atorvastatin, sertraline, citalopram, and lisinopril. Tablet splitting was considered a reasonable strategy for these agents because the tablets
A B S T R A C T
OBJECTIVE: The primary objective was to determine the effect of a hydroxymethylglutaryl-CoA reductase inhibitor (HMG) tablet-splitting program on laboratory outcomes (lipid panel and liver enzyme tests). Other objectives were to assess patient compliance and satisfaction with splitting tablets and to measure the reduction in drug acquisition costs.
METHODS: Patients at a Veterans Affairs Health Care System facility were included in this study if they participated in the HMG tablet-splitting program between April and September 2000. Patients taking the same drug and dosage before and after implementation of the program were asked to complete a mailed questionnaire designed to measure satisfaction and compliance with the program. Data collected through electronic charts included patient demographics, prescribed medication, and the values for lipid panel and liver function tests.
RESULTS: A total of 2,019 patients were included in the study. The total cost avoidance achieved over one year for atorvastatin, lovastatin, and simvastatin was $138,108 (N=2,019). The majority of patients who responded to the questionnaire were satisfied and compliant with tablet splitting. In the laboratory analysis (N=512), there was no difference between prevalues and postvalues for total cholesterol and triglycerides. There was a statistically, but not clinically, significant decrease in LDL (102 versus 97, P<0.001) and increase in HDL (46 versus 48, P<0.001), AST (26 versus 28, P<0.001), and ALT (24 versus 26, P=0.006) after the initiation of tablet splitting.
CONCLUSION: Tablet splitting of HMGs had no short-term negative effects on laboratory outcomes and favorable effects on humanistic outcomes as measured by patient satisfaction and compliance. Tablet splitting of HMGs is an effective way to reduce costs and nearly double the number of patients who can be treated for the same expense. Before entering our program, patients were evaluated by the prescribing provider or an outpatient pharmacist for cognitive and physical barriers to assess whether or not they were able to effectively split the tablets in half. The provider could request that the prescription be filled with whole tablets if that provider determined the patient to be ineligible for the tablet-splitting program. If the provider did not indicate tablet splitting in the medication order, the pharmacist would then evaluate the patient for the tablet-splitting program. The pharmacist evaluation consisted of a brief review of the patient' s electronic medical record and a patient interview. If patients agreed to participate in the program, prescriptions were automatically converted by a pharmacist. A tablet splitter and instructions for use were also provided free of charge to patients. All patients were allowed to decline entry into the program upon request.
Because HMGs have objective clinical outcome measures that are consistent, easy to compare, and readily retrievable, we chose to focus our review on these agents. The primary objective of the study was to determine the effect of splitting atorvastatin, lovastatin, and simvastatin tablets on laboratory outcomes (lipid panel and liver enzyme tests). Other objectives of the study were to assess patient compliance and satisfaction with splitting tablets and to measure the reduction in drug acquisition costs.
■■ Methods
The study was conducted in the outpatient setting of the Veterans Affairs Palo Alto Health Care System. The study was conducted in 3 phases. In Phase I, a cost-avoidance analysis was conducted. In Phase II, patient compliance and satisfaction were measured using a patient questionnaire. In Phase III, laboratory outcomes were analyzed. The study protocol was approved by the Institutional Review Board, and all patients gave written, informed consent prior to enrollment.
Phase I: Cost Avoidance
Patients were included in Phase I of the study if they were enrolled in our HMG tablet-splitting program between April 1, 2000, and September 30, 2000. The HMGs used at our institution were atorvastatin, lovastatin, and simvastatin (cerivastatin, fluvastatin, and pravastatin were not on the formulary). The patients were identified using the computerized pharmacy prescription database. To determine the cost avoidance in these patients, we obtained prescription records for HMGs in these patients over a one-year period (October 2000 to September 2001). Using the 2000-2001 VA actual drug acquisition cost for atorvastatin, lovastatin, and simvastatin, we calculated the cost of these prescriptions utilizing tablet splitting.
The calculation for cost avoidance per dose was: The cost avoidance per dose was multiplied by the total amount of doses filled by all the patients. The 2000-2001 VA acquisition cost of the tablet splitters was then subtracted to calculate the overall cost avoidance.
Phase II: Patient Compliance and Satisfaction
Patients from Phase I who were on a stable dosage of an HMG for 12 weeks were enrolled in Phase II. A stable dosage was defined as no change in dosing of the HMG 6 weeks before and 6 weeks after tablet splitting was initiated. Patients were excluded prior to this phase if (a) therapy was initiated using split tablets, (b) there was a drug or dosage change at the time of conversion to tablet splitting or anytime within the 12 weeks, or (c) the patient was converted back to whole tablets within 6 weeks. Questionnaires were mailed to patients in January 2001, after the first exclusion phase, in order to measure both compliance and satisfaction with our tablet-splitting program ( Figure 1 ). The questionnaire was adapted from the survey that was used in a prior study conducted by Carr-Lopez et al. 1 On the questionnaire, 4 questions were designed to measure satisfaction and 2 questions were designed to measure compliance. The other questions served to identify which drug was split, how it was taken, and to determine the logistics of tablet splitting. Responses were collected through April 2001.
Phase III: Laboratory Outcomes
The Phase III laboratory analysis was conducted on all patients in Phase II who had lipid panels drawn and recorded both before (prelab) and after (postlab) tablet splitting. The prelab was defined as a lipid panel taken between one year before and the day that tablet splitting was initiated. The postlab was defined as a lipid panel taken between 6 weeks and one year after tablet splitting was initiated. In patients with more than one preintervention and/or more than one postintervention lipid panel within the study period, the panel values closest to initiation of tablet splitting were used. Patients were excluded from Phase III analysis if the postintervention lab values were taken (a) within 6 weeks postconversion to tablet splitting, (b) after a drug or dosage change, or (c) if an interacting drug was initiated within 6 weeks of the lab test. Interacting drugs included cholestyramine, colestipol, cyclosporine, erythromycin, fenofibrate, gemfibrozil, nefazodone, niacin, phenytoin, antifungals (itraconazole, ketoconazole, fluconazole), and protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, abacavir).
To measure outcomes of tablet splitting, we evaluated lipid panels, liver enzyme tests, and creatine phosphokinase (CPK) laboratory values. Lipid panels included total cholesterol (TC), For both the lipid panels and liver enzyme tests, we compared the prelabs with the postlabs to determine if there was a change. CPK was used to identify if any patient experienced rhabdomyolysis after tablet splitting was initiated.
In a post hoc subgroup analysis, the laboratory results of dissatisfied and noncompliant patients identified from the questionnaires were compared. A dissatisfied patient was defined as anyone who had a negative response to all 4 questions that pertained to satisfaction. A noncompliant patient was defined as anyone who responded negatively to either of the questions pertaining to compliance.
Statistical Analysis
Interval data (TC, LDL, TG, HDL, AST, ALT) is presented as mean ± standard deviation, and comparisons were evaluated using the paired t test. For data that were not normally distributed (i.e, ALT), the data are presented as medians and compared using the Wilcoxon signed rank test. Statistical tests were performed using Sigma Stat (Version 2, Jandel, Sausalito, CA).
■■ Results
We identified 2,019 patients enrolled in the HMG tablet-splitting program. The total cost avoidance over one year (October 2000 to September 2001) for atorvastatin, lovastatin, and simvastatin was $138,108 (Table 1) , based upon actual acquisition costs for these 3 drugs.
After the cost-avoidance analysis, 1,111 patients were excluded prior to the Phase II analysis ( Table 2) . The remaining 908 patients were mailed questionnaires ( Table 2) . We received 454 responses (50%). Of the respondents, 83% were splitting simvastatin, 15% lovastatin, and 2% atorvastatin. These percentages are consistent with the overall use of these medications at our institution.
Patient satisfaction and compliance with tablet splitting were determined from the questionnaires. There were 4 questions that addressed patient satisfaction. The results of these questions showed that 84% believed that the tablet splitter was not difficult to use, 85% stated that split tablets were not harder to take compared to whole tablets, and 74% agreed that the tablet splitter was not too time-consuming or bothersome; 46% believed that it was easier to take medications when they did not have to split the tablets.
There were 2 questions that addressed patient compliance. Only 7% of the patients stated that tablet splitting had an effect on their willingness to take medications, and 7% stated that they missed more doses in a month while tablet splitting.
Five hundred-twelve patients were eligible for the laboratory analysis. The baseline demographics for these patients are listed in Table 3 . The laboratory analysis showed that there was no difference between preintervention and postintervention laboratory values for total cholesterol and triglycerides (Table 4) In the subgroup analysis, the laboratory results of the dissatisfied and noncompliant (self-reported) patients identified from the questionnaires were analyzed. There was no significant change in the laboratory values between preintervention and postintervention. (Table 5 ).
■■ Discussion
This study suggests that tablet splitting for HMGs has no negative effects on lipid panels or liver enzyme tests. This study is larger than the previous studies that address tablet splitting and is the first one to measure laboratory outcomes that include changes in liver enzyme tests or adverse patient events associated with splitting HMG tablets.
In the laboratory analysis, there was no change in total cholesterol and triglycerides, but there was a statistically significant decrease in LDL and a statistically significant increase in HDL. Our findings are very similar to those reported by Duncan et al. 4 The changes in LDL and HDL are most likely beneficial for the patients; however, the clinical significance and reasons for the changes are uncertain. There were also statistically significant increases in the liver enzyme tests, AST and ALT; however, these increases do not appear to be clinically significant since the levels of both the AST and ALT after the change are well within the normal range for these tests.
Among possible limitations of our study, the positive outcomes may be attributable in part to the screening process involved. Not all patients can split tablets in half effectively with a pill splitter, and, therefore, not all patients should be included in tablet-splitting programs. Patients who might be excluded from tablet-splitting programs include those with eyesight problems, arthritis in the hands, or cognitive impairment. To avoid some of these problems, outpatient pharmacists assessed the patients for both cognitive and physical barriers before initiating them in the program. If the pharmacist determined that the patient could not effectively split the tablets in half, a note was left in the patient' s medication profile stating not to enter the patient into the tablet-splitting program.
Another factor that may have contributed to the favorable laboratory outcomes is lifestyle modification. While we assessed laboratory outcomes up to 12 months postsplitting, we did not give consideration to changes in weight, smoking status, alcohol consumption, or dietary modifications during that time. Any of these factors may have influenced laboratory values. In addition, our study was not designed to objectively assess medication compliance using methods such as a pill count or refill analysis. This would have been particularly useful to ensure that patients were indeed taking split tablets (and not whole tablets), which could also have affected the laboratory outcomes.
The majority of patients included in the study were satisfied and compliant with the HMG tablet-splitting program, as shown from the questionnaire results. For the few patients identified as noncompliant or dissatisfied with the program, it was important to analyze whether splitting tablets was adversely affecting their outcomes. Neither the dissatisfied nor noncompliant patients had any significant changes in their lipid panels and liver enzyme tests when comparing their laboratory values before and after tablet splitting. These results suggest that tablet splitting is also effective in these patients; however, additional results from a larger study designed a priori to specifically address this question are necessary.
The HMG tablet-splitting program reduced actual outpatient drug acquisition costs by more than $138,000 for our likely an underestimate of the total fiscal impact of the program over this one-year time frame. In addition, this analysis only takes into account the effect of splitting HMGs. The tablet-splitting strategy is used for a continually growing list of agents in our outpatient setting, resulting in cost avoidance of even greater magnitude. Finally, it is important to note that VA drug acquisition costs, which are considerably lower than average wholesale price, were used in our calculations. Therefore, other managed care organizations that face higher drug acquisition costs could expect a more substantial cost avoidance. Unfortunately, due to the retrospective nature of this analysis, we were unable to precisely factor pharmacist time and effort into our analysis. These factors are, of course, very important to consider before implementing a program of this nature. If we were to assume that it took an extra 5 to10 minutes for our pharmacist to counsel and educate the 2,019 patients, it would result in an opportunity cost of 168 to 336 pharmacist hours. Still, our cost avoidance was not offset by pharmacist salary because no additional staff were employed to implement this program.
With the recent availability of generic lovastatin, many institutions may benefit foremost from converting appropriate patients requiring HMGs to lovastatin. However, because generic lovastatin is considerably more expensive than Mevacor at our institution, and it is not flat or similar priced, we continue to use the brand-name product. Furthermore, at low doses of lovastatin (10 mg and 20 mg), the dose equivalent of simvastatin is less expensive, so we continue to offer both agents.
Another possible limitation to our study was that we had to exclude a large number of patients in phase II because they did not receive a postintervention laboratory panel. However, there is nothing to suggest that the patients who did not receive a postlab would have responded to tablet splitting differently than those patients who did receive postintervention laboratory testing. This ancillary finding is nonetheless important and enables us to target provider and patient education regarding the importance of appropriate follow-up laboratory monitoring.
An additional limitation to our study was that the questionnaire was not sent to all patients. We chose not to send out the questionnaire to patients who had drug or dosage changes at the time of tablet splitting. Our goal from the questionnaire was to determine the effects of tablet splitting on patient satisfaction and compliance while taking the same drug and dosage before and after initiation of the program. We felt that satisfaction and compliance could be affected if patients were on a different medication or if they had to swallow a different size tablet. Therefore, it would not be ideal to find out how satisfied or compliant patients were with one medication or dose before splitting and compare it to another one after they started splitting. If we wanted a broader analysis to determine what patients thought of tablet splitting in general, then we could have included these patients in the questionnaire analysis as well.
The positive results from our study reinforce and expand upon the findings presented by Duncan, et al. 4 This study should be useful for many institutions and opens the door to future directions. It would be beneficial to assess outcomes of tablet splitting for other medications, such as antihypertensives and antidepressants. It will also be useful to determine significant patient barriers to effective tablet splitting.
■■ Conclusion
Splitting HMG tablets is an effective way to reduce outpatient drug costs, improving the efficiency in treatment of hypercholesterolemia. We found favorable humanistic-service outcomes (patient satisfaction and compliance) and no short-term negative effects on laboratory outcomes associated with tablet splitting of HMG drugs for outpatients at our institution.
